Article · Supply Chain Strategy
Most multi-facility orthopedic groups have tried to standardize tissue purchasing at some point. Most of them stopped trying.
Most multi-facility orthopedic groups have tried to standardize tissue purchasing at some point.
Most of them stopped trying — not because standardization doesn't make financial sense, but because the path to getting there often runs directly through surgeon preferences — and surgeon preferences can be as much a relationship challenge as an operational one.
Here's what that usually looks like in practice:
A supply chain manager identifies the opportunity — consolidating tissue volume under one preferred provider would improve pricing, simplify compliance documentation, and reduce the administrative burden on individual facilities. The economics are clear. The pitch to leadership goes well.
Then it hits the OR.
One surgeon has used the same tissue bank for twelve years and isn't changing. Another has a long-standing relationship with a specific rep. A third has strict processing preferences that the preferred provider "can't always guarantee." The standardization initiative quietly stalls, and tissue purchasing reverts to a facility-by-facility, surgeon-by-surgeon patchwork.
Sound familiar?
The most common mistake in tissue standardization initiatives is targeting 100% compliance.
It's the wrong goal. It's politically untenable, operationally impractical, and ultimately unnecessary to capture the financial benefit you're looking for.
The facilities and groups that successfully standardize tissue purchasing don't mandate a single source for every surgeon. They build a program that captures the majority of volume — typically 80–85% — under a preferred provider model, while preserving structured flexibility for the surgeons who won't change.
The result: the pricing leverage and compliance consistency of standardization, without the political fight of a mandate nobody will enforce.
When a surgeon says "I only use [Tissue Bank X]," the underlying reason often falls into one of a few common categories:
They want a specific graft type, diameter, donor age, or processing method. If that specification is available through a different source, the bank itself may not matter — they just don't know it.
They have a personal or professional connection to someone at that bank. This is real and worth acknowledging rather than fighting.
They've always done it this way and haven't been given a reason to change.
The first category — spec preference — represents the majority of surgeon "bank loyalty" in practice. And it's the most solvable, because specifications can be sourced across banks. A preferred provider with access to multiple accredited tissue banks can satisfy most spec requirements without requiring the surgeon to change what they're asking for.
The highest-performing orthopedic groups approach tissue standardization in three steps:
Work with each surgeon to understand what they actually require — graft type, diameter, length, donor age, processing method. Document this formally. You'll often find that the "requirements" are narrower than assumed, and that what looked like bank loyalty is actually just a spec preference that can be satisfied elsewhere.
For surgeons whose preferences genuinely require a specific source, build that into the program from day one as an accommodated exception. Don't fight it. A program that accounts for the outliers in writing is more durable than one that pretends they don't exist.
Standardization success isn't 100%. It's capturing 80–85% of your tissue volume under one program with documented pricing, consistent compliance infrastructure, and a single point of accountability. That's where the financial and operational benefit lives — and it's achievable without a mandate.
When standardization is structured this way, it creates something that per-case or facility-by-facility purchasing cannot:
That last point is underappreciated. In a multi-facility group, inventory that exists somewhere in your network but isn't visible to the facility that needs it is effectively wasted. Visibility across locations converts that waste into supply reliability.
If your organization has tried tissue standardization before and it stalled, the right question isn't "why didn't it work?" It's "were we targeting the right goal?"
Eighty percent of the benefit doesn't require one hundred percent of the compliance. And the groups that understand that distinction are the ones who actually get it done.
Continue Reading